• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
  • Newsroom
    • Scientific Publications
    • Press Releases
    • Events
  • Partnering
  • Investors
    • Overview
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us

9th Annual CAR-TCR Summit (Boston, Sep. 17-20)

September 3, 2024 Caroline Lonez

Our team will be presenting at CAR-TCR Summit! Please join us at the Cell Therapy Fundamentals Day!

BIO-Europe (Stockholm, Nov. 4-6)

September 3, 2024 Caroline Lonez

Our team will be attending BIO-EUROPE, the largest partnering conference in the life sciences sector in Europe, focusing on the biotechnology and pharmaceutical industries!

We will be happy to meet you there! Find our company in the partnering system for potential meetings.

Recent insights into Immuno-Oncology (Antwerp, May 30-31)

May 29, 2024 Caroline Lonez

Our team will be attending and presenting two posters at the VIB conference around insights into Immuno-Oncology.

Pharma Partnering EU Summit (Basel, May 22-23)

May 20, 2024 Caroline Lonez

Our team will be attending the Pharma Partering EU Summit in Basel! Meet us there!

InnoXpo Seasonal Roadshow (Virtual, April 18)

April 16, 2024 Caroline Lonez

bioSeedin InnoXpo CGT roadshow will be held online and Celyad Oncology is one of the six presenting companies.

27th Annual Meeting of ASGCT (Baltimore, May 7-11)

March 29, 2024 Caroline Lonez

Our team will be participating to the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).

We will be presenting two posters:

  • Abstract 837:Generation of Allogeneic CAR T-Cells Using an Easy, Safe, and Effective Non-Gene Editing Technology. Poster presentation during the Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies Poster Session on Wednesday May 8 (12:00 PM).
  • Abstract 1800: PSMA/NKG2DL Tandem CAR T-cells to overcome antigen heterogeneity and improve anti-tumor efficacy against prostate cancer. Poster presentation during the Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies Poster Session on Friday May 10 (12:00 PM).
  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 15
  • Go to Next Page »

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Newsroom
  • Partnering
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2026 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use